We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PENG
1826
Penguin Solutions Inc
PENG
$2.83B
| $335K | ﹤0.01% |
20,447
+1,749
| +9% | +$39.9K |
|
1827
Workiva
WK
$3.66B
| $333K | ﹤0.01% |
5,044
-5,263
| -51% | -$438K |
|
1828
Boot Barn
BOOT
$5.11B
| $332K | ﹤0.01% |
4,823
-13,775
| -74% | -$1.18M |
|
1829
Coherus Oncology
CHRS
$192M
| $332K | ﹤0.01% |
45,882
-31,826
| -41% | -$277K |
|
1830
Pebblebrook Hotel Trust
PEB
$2B
| $332K | ﹤0.01% |
20,442
+1,360
| +7% | +$30K |
|
1831
Precision BioSciences
DTIL
$206M
| $330K | ﹤0.01% |
6,869
-369
| -5% | -$21.7K |
|
1832
Webster Financial
WBS
$12.8B
| $330K | ﹤0.01% |
7,909
-5,653
| -42% | -$272K |
|
|
TEN
1833
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $330K | ﹤0.01% |
19,232
-603
| -3% | -$10.2K |
|
1834
Anika Therapeutics
ANIK
$277M
| $328K | ﹤0.01% |
+14,705
| New | +$328K |
|
1835
POSCO
PKX
$17.7B
| $328K | ﹤0.01% |
7,363
-496
| -6% | -$27.3K |
|
1836
Columbus McKinnon
CMCO
$557M
| $327K | ﹤0.01% |
11,518
+2,250
| +24% | +$77.4K |
|
1837
AngioDynamics
ANGO
$651M
| $326K | ﹤0.01% |
16,836
-35,396
| -68% | -$725K |
|
|
BRT
1838
BRT Apartments
BRT
$266M
| $325K | ﹤0.01% |
+15,141
| New | +$334K |
|
1839
Vericel Corp
VCEL
$2.25B
| $325K | ﹤0.01% |
12,911
-19
| -0.1% | -$561 |
|
1840
United Bankshares
UBSI
$6.55B
| $324K | ﹤0.01% |
9,397
-50,117
| -84% | -$1.76M |
|
1841
Granite Construction
GVA
$5.51B
| $321K | ﹤0.01% |
11,013
-1,330
| -11% | -$41.3K |
|
1842
VF Corp
VFC
$5.86B
| $321K | ﹤0.01% |
+7,390
| New | +$371K |
|
1843
CEVA Inc
CEVA
$889M
| $320K | ﹤0.01% |
9,528
-5,392
| -36% | -$190K |
|
1844
American Outdoor Brands
AOUT
$160M
| $319K | ﹤0.01% |
33,571
+2,237
| +7% | +$26.5K |
|
1845
PDF Solutions
PDFS
$2.01B
| $318K | ﹤0.01% |
14,780
-10,029
| -40% | -$232K |
|
|
KRTX
1846
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $318K | ﹤0.01% |
+2,513
| New | +$289K |
|
1847
BioCryst Pharmaceuticals
BCRX
$2.51B
| $317K | ﹤0.01% |
29,917
-26,762
| -47% | -$276K |
|
|
KZR
1848
DELISTED
Kezar Life Sciences
KZR
| $317K | ﹤0.01% |
3,827
+2,333
| +156% | +$206K |
|
1849
Astrana Health
ASTH
$1.86B
| $314K | ﹤0.01% |
8,129
+1,713
| +27% | +$65.2K |
|
|
DEA
1850
Easterly Government Properties
DEA
$1.13B
| $312K | ﹤0.01% |
6,560
-3,548
| -35% | -$173K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.